Liprolog Mix50 Kwikpen (Insulin Lispro)

Insulin lispro is a rapid‑acting insulin analog that lowers post‑prandial glucose by facilitating cellular uptake.

• Type 1 diabetes mellitus: provides mealtime glucose control and reduces hyperglycaemia episodes.
• Type 2 diabetes mellitus: improves post‑meal glucose excursions when used with basal insulin or oral agents.

• Insulin lispro binds to the insulin receptor on cell membranes, activating the receptor’s intrinsic tyrosine kinase activity. This triggers downstream signaling that promotes translocation of GLUT‑4 transporters to the cell surface, enhancing glucose uptake in muscle and adipose tissue while suppressing hepatic glucose production, resulting in rapid reduction of circulating glucose.

Insulin lispro may cause a range of adverse reactions.

Common Side Effects

• Hypoglycaemia: low blood glucose levels, especially if meals are missed or delayed.
• Injection site reactions: redness, swelling, or itching at the injection site.
• Weight gain: modest increase associated with improved glycaemic control.
• Lipodystrophy: localized changes in subcutaneous fat with repeated injections.
• Mild nausea or gastrointestinal discomfort.

Serious or Rare Side Effects

• Severe hypoglycaemia: neurological symptoms requiring immediate assistance.
• Allergic reactions: urticaria, angioedema, or anaphylaxis.
• Hypokalemia: low potassium levels in rare cases.
• Persistent hyperglycaemia despite dosing adjustments.
• Injection‑site infection or abscess formation.

Insulin lispro requires careful monitoring and individualized dosing.

• Blood glucose monitoring: check levels before meals and at bedtime to adjust dose.
• Exercise considerations: reduce dose or carbohydrate intake when planning vigorous activity.
• Hypoglycaemia unawareness: use caution in patients who cannot perceive low glucose symptoms.
• Renal or hepatic impairment: may need dose modification and closer monitoring.
• Pregnancy and lactation: assess risk‑benefit ratio; insulin is generally preferred but consult a specialist.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the pen.

Insulin lispro can interact with several drug classes, altering glucose control.

Major Interactions (Avoid)

• Concurrent sulfonylureas or meglitinides: increased risk of severe hypoglycaemia.
• Beta‑blockers: may mask hypoglycaemia symptoms, complicating detection.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: may potentiate insulin’s glucose‑lowering effect.
• Thiazide diuretics: can raise blood glucose, requiring dose adjustment.
• Oral contraceptives or hormone therapy: may increase insulin requirements.